CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ALPMY

tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)

Phase 3
Astellas Pharma (ALPMY)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Lower Urinary Tract Symptoms

View Full Landscape
Drug Information

Target Indication

Lower Urinary Tract Symptoms

Clinical Trial

NCT01021332

Last updated: 12/25/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.